13-Mar-2026
Analysts Are Bullish on Top Healthcare Stocks: Caribou Biosciences (CRBU), Oncology Institute (TOI)
TipRanks (Mon, 9-Mar 7:30 AM ET)
Globe Newswire (Thu, 5-Mar 4:05 PM ET)
Caribou Biosciences to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 12-Feb 4:05 PM ET)
Globe Newswire (Wed, 4-Feb 8:00 AM ET)
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Globe Newswire (Wed, 24-Dec 6:00 AM ET)
Market Chameleon (Mon, 3-Nov 4:54 AM ET)
Market Chameleon (Mon, 3-Nov 2:05 AM ET)
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focsued on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Caribou Biosciences trades on the NASDAQ stock market under the symbol CRBU.
As of March 13, 2026, CRBU stock price declined to $1.88 with 745,646 million shares trading.
CRBU has a beta of 2.20, meaning it tends to be more sensitive to market movements. CRBU has a correlation of 0.23 to the broad based SPY ETF.
CRBU has a market cap of $175.72 million. This is considered a Micro Cap stock.
Last quarter Caribou Biosciences reported $4 million in Revenue and -$.28 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.04.
In the last 3 years, CRBU traded as high as $8.59 and as low as $.66.
The top ETF exchange traded funds that CRBU belongs to (by Net Assets): VTI, VXF, IBB, SCHA, NXTE.
CRBU has outperformed the market in the last year with a price return of +90.8% while the SPY ETF gained +21.4%. CRBU has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.0% and -1.1%, respectively, while the SPY returned -2.6% and -3.5%, respectively.
CRBU support price is $1.77 and resistance is $2.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRBU shares will trade within this expected range on the day.